Passive properties of the myocardium influence diastolic filling and cardiac output. In heart failure, changes in contributors to the passive properties of the ventricle, such as titin and collagen, and loss of the metabolic enzyme creatine kinase, increase resistance to filling resulting in diastolic dysfunction. Pulmonary artery hypertension (PAH) arises from interactions between the pulmonary vasculature and the right ventricle (RV) which ultimately leads to RV failure. Beta1-adrenergic receptor blockers (BB) act on the myocardium and are beneficial in left heart failure but are not used in PAH. We investigated whether BB improved survival and RV function in a rat model of PAH. Rats were injected with monocrotaline (60 mg/kg) to induce PAH and RV failure, or saline as controls (CON). When PAH was established, rats were treated with metoprolol (10 mg/kg per day) (MCT+BB) or vehicle (sucrose) (MCT); CON were treated with vehicle. In vivo measurement of RV compliance using pressure-volume catheter, indicated diastolic dysfunction in the RV of MCT rats was improved with BB treatment. Expression of creatine kinase protein and mRNA was lower in MCT rats compared to CON, with a trend for reversion by BB treatment.
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Summary
Passive properties of the myocardium influence diastolic filling and cardiac output. In heart failure, changes in contributors to the passive properties of the ventricle, such as titin and collagen, and loss of the metabolic enzyme creatine kinase, increase resistance to filling resulting in diastolic dysfunction. Pulmonary artery hypertension (PAH) arises from interactions between the pulmonary vasculature and the right ventricle (RV) which ultimately leads to RV failure. Beta1-adrenergic receptor blockers (BB) act on the myocardium and are beneficial in left heart failure but are not used in PAH. We investigated whether BB improved survival and RV function in a rat model of PAH. Rats were injected with monocrotaline (60 mg/kg) to induce PAH and RV failure, or saline as controls (CON). When PAH was established, rats were treated with metoprolol (10 mg/kg per day) (MCT+BB) or vehicle (sucrose) (MCT); CON were treated with vehicle. In vivo measurement of RV compliance using pressure-volume catheter, indicated diastolic dysfunction in the RV of MCT rats was improved with BB treatment. Expression of creatine kinase protein and mRNA was lower in MCT rats compared to CON, with a trend for reversion by BB treatment.
Isolated CON RV myocytes had a positive contraction response to faster pacing, whereas it was negative in MCT. MCT+BB cells had an intermediate response, indicating improved ability to respond to increased demand. BB improved diastolic function, partially restored metabolic enzymes and augmented contractility in PAH. These data support the hypothesis that BB may be beneficial in PAH by supporting RV function.
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| DIASTOLIC DYSFUNCTION AND HEART FAILURE
Ventricular stroke volume is influenced by end-diastolic volume through the Frank-Starling mechanism. This dictates that as the ventricle fills, sarcomeres are stretched along the ascending limb of the length-tension relationship, resulting in greater myofilament force generation and ejection of blood. In pathological conditions, such as heart failure, increased resistance to ventricular filling may reduce end-diastolic volumes and thereby cause a decrease in stroke volume and cardiac output. This limits the ability of the heart to respond to an increase in demand, which is a definition of heart failure. Myocardial passive properties are implicated in diastolic Presented at the Cardiomyocyte Mechano-and Myofilament Dysfunction in Heart Failure Progression Symposium at the joint AuPS and ASB meeting, Adelaide, 2016. The papers in these proceedings were peer reviewed under the supervision of the AuPS Editor.
dysfunction. During normal filling, a major contribution to passive tension is thought to come from titin, an elastic protein that spans half of the sarcomere from Z-disk to M-line. Changes in the properties of titin in disease are known to include a shift in isoform distribution from the more compliant N2BA isoform to the shorter and stiffer N2B isoform, oxidation of cysteine residues, and phosphorylation status. 
| PULMONARY ARTERY HYPERTENSION AND DIASTOLIC DYSFUNCTION
Pulmonary artery hypertension (PAH) is a complex disease with interactions between the pulmonary vasculature (PV) and the right ventricle (RV). It is caused by increased constriction of the PV which increases vascular resistance and hence RV afterload. This eventually leads to RV failure, which is the most common cause of death in PAH.
In the study of Rain et al 9 human PAH patients were found to have diastolic dysfunction. There was increased stiffness of myocardium, increased collagen content and reduced phosphorylation of titin with no shift in titin isoforms. RV failure has also been studied in animal models of PAH. 10 In the monocrotaline rat model of PAH, RV heart failure occurs 3-4 weeks after a single injection of monocrotaline. The onset of heart failure in this model was associated with diastolic dysfunction. 11 When a reduced dose of monocrotaline was used to induce stable hypertrophy, diastolic function was preserved.
12
We have used the monocrotaline rat model to study RV failure in PAH. The end diastolic pressure-volume relationship (EDPVR) was measured using a Millar catheter inserted into the RV of anesthetized animals. The EDPVR was significantly steeper in monocrotaline- ing CK inhibition. We interpreted this as a decreased ability of MCT myocytes to respond to an increase in demand, which is a definition of heart failure. We concluded that decreased CK expression leads to diastolic dysfunction, via local reduction in ATP:ADP ratio and thus to Ca 2+ -independent force production and diastolic sarcomere shortening.
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| BETA-BLOCKER TREATMENT OF PAH
There is currently no cure for PAH and novel treatments are needed to resolve this. The importance of RV function in PAH patient survival indicates the heart is a potential therapeutic target. However, available therapies primarily cause vasodilation of the PV and current guidelines do not include treatments specifically for the RV. injected with saline and given sucrose.
As we were specifically interested in the cardiac effects of beta-blocker treatment we chose to use metoprolol: it is beta-1 specific (the predominant beta-adrenoceptor in heart), in common clinical use, and lacks the vasodilatory effects of carvedilol 18 and nebivolol. 19 The human equivalent dose of 10 mg/kg per day Table 1 and show RV hypertrophy in both PAH groups. EDPVRs were measured in anaethetised rats by Millar catheter in the RV during vena cava occlusion ( Figure 1A , see Fowler et al. 13 for details of methodology). The EDPVR from MCT animals was significantly steeper than CON, indicating diastolic dysfunction. The mean value for MCT+BB was intermediate ( Figure 1B) representing an improvement in diastolic function. Consistent with observations in whole animals, the resting sarcomere length of RV myocytes showed a progressive increase CON > MCT+BB > MCT ( Figure 1C ). BB treatment did not affect diastolic or systolic pulmonary pressure, consistent with previous reports using other BB 18, 19 , but did improve the ratio of end systolic pressure-volume relationship (ESPVR) to arterial elastance (Ea), an indicator of in vivo contractility/afterload (see Table 1 ).
T A B L E 1 Animal and organ characteristics of rats on the median day of heart failure signs (CON and MCT+BB) or day of heart failure signs (MCT) On the final experimental day there was RV hypertrophy in MCT and MCT+BB animals compared with CON. RV systolic and diastolic pressure were increased in MCT and MCT+BB animals. Ventriculo-arterial coupling was impaired in MCT (reduced end-systolic pressure-volume relationship (ESPVR) to arterial elastance (Ea) ratio) but not different in MCT+BB compared to CON. *P < .05, one-way ANOVA. Intergroup differences between variables were identified using Dunn's (RV:LV+S and End systolic pressure) or Tukey's (all others) post hoc test. CON, control; MCT, monocrotaline treated; MCT+BB, monocrotaline + beta-blocker treated; LV, left ventricle; RV, right ventricle; S, septum 
| CONCLUSIONS
Data for CON and MCT groups confirm the findings from our previous study. 13 In addition, we show that parameters modulated by PAH consistently show means intermediate to CON and MCT following beta-blocker therapy. This suggests beta-blocker treatment may contribute to delaying the onset of heart failure by reducing maladaptive cellular remodelling within the RV. That these effects on the myocardium were achieved in the absence of improvement in lung weights or pulmonary artery pressure suggest they are due to direct effects on the myocardium. This interpretation would support the use of beta-blockers as an adjunct to, rather than a replacement for, conventional treatments for PAH. Despite increasing pre-clinical evidence supporting a beneficial effect and revealing their mode of action, the use of beta-blockers to treat PAH is at present controversial, 17 and further data from clinical trials are required.
F I G U R E 3 Beta-blocker treatment partially restored the profile of isolated RV myocyte contraction-frequency relationships. (A), Unloaded sarcomere fractional shortening was recorded in isolated cells electrically paced at 1 Hz. Shortening was greater in MCT than CON and MCT+BB (*P < .05, one-way ANOVA with Tukey's post hoc test). (B), Shortening normalised to values at 1 Hz. When stimulation frequency was increased to 7 Hz CON myocytes showed a positive response whereas the response in MCT was negative. The response of MCT+BB was intermediate demonstrating an increased ability to maintain contraction amplitude in response to the increase in demand (n = 22-30 myocytes from N = 6 rats per group). Only cells which contracted regularly at 7 Hz were included for analysis. *P < .05 vs CON, † P < .05 vs MCT+BB. Within-group response to frequency was assessed using one-way repeated measures ANOVA. Between-group differences at each frequency were identified using one-way ANOVA with Dunn's post hoc test while accounting for multiple comparisons using the Bonferroni method CON, control; MCT, monocrotaline treated; MCT+BB, monocrotaline + beta-blocker treated
